Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients

British Journal of Clinical Pharmacology

Volumn 44, Issue 6, 1997, Pages 537-542

  Akhlaghi, Fatemeh ^a   McLachlan, Andrew J ^a   Keogh, Anne M ^b   Brown, Kenneth F ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Clearance; Cyclosporine; Drug interaction; Fraction unbound; Heart transplant; LDL cholesterol; Lipoproteins; Population pharmacokinetics; Simvastatin

Indexed keywords

CYCLOSPORIN; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INTERACTION; FEMALE; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030691990     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00625.x     Document Type: Article

References (30)

1. Borel JF, Kis ZL. The discovery and development of cyclosporine. Transplant Proc 1991; 23: 1867-1874.
2. Niederberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983; 15 (Suppl 1): 2419-2421.
3. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporine in blood. J Pharm Pharmacol 1982; 34: 715-718.
4. Lindholm A, Henricsson S, Lind M, Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporine after oral dosing. Eur J Clin Pharmacol 1988; 34: 461-464.
5. Keogh A, Simons L, Spratt P, et al. Hyperlipidemia after transplantation. J Heart Transplant 1988; 7: 171-175.
6. Geo SZ, Schroeder JS, Alderman EL, et al. Clinical and laboratory correlation of accelerated coronary artery disease in the cardiac transplant patients. Circulation 1987; 76: 56-61.
7. Keogh AM. Coronary artery disease in cardiac transplant recipients. Med J Aust 1995; 163: 212-214.
8. Arnadottir M, Eriksson L-O, Germershausen JI, Thysell H. Low-dose simvastatin is well-tolerated and efficacious cholesterol lowering agent in cyclosporine-treated kidney transplant recipients: Double blind, randomised, placebo-controlled study in 40 patients. Nephron 1994; 68: 57-62.
9. Rehman MA, Al-Sulaiman MH, Mousa DH, et al. Effects of simvastatin in hyperlipidaemic renal transplant patients receiving cyclosporine. Transplantation 1995; 60: 397-399.
10. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of Pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
11. Venkataramanan R, Ptachinski RJ, Burckart GJ, Yang S, Starzl TE. Extraction ratio of cyclosporine in a liver transplant patient with organ rejection. J Pharm Sci 1985; 74: 901-902.
12. Rowland M. Protein binding and drug clearance. Clin Pharmacokinet 1984; 9: 10-17.
13. Lithell H, Odlind B, Selinus A, Lindberg B, Lindstorm B, Frodin L. Is the plasma lipoprotein pattern of importance for treatment with cyclosporine? Transplant Proc 1986; 23; 50-51.
14. Awni WM, Heim-Duthoy K, Kasiske BL. Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients. Transplant Proc 1990; 22: 1193-1196.
15. de Lorgeril M, Boissonnat P, Bizollan CA, et al. Pharmacokinetics of cyclosporine in long-term survivors of heart transplantation, lack of interaction with lipid lowering agent, fenofibrate. Eur J Clin Pharmacol 1992; 43: 161-165.
16. Akhlaghi F. Distribution of cyclosporine in plasma from cardiopulmonary transplant recipients. PhD dissertation, Sydney: University of Sydney, 1996.
17. Keogh A, Spratt P, McGosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. New Engl J Med 1995; 333: 628-633.
18. Gornall BP, Bardawill CJ, David MA. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949; 177: 751-766.
19. Rowland M and Tozer TN. In Clinical pharmacokinetics: concepts and applications. Third edition, Philadelphia and London: William & Wilkins, 1995.
20. Grevel J, Post BK, Kahan BD. Michaelis-Menten kinetics determine cyclosporin steady-state concentrations: A population analysis in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 651-660.
21. Kronbach T, Fisher V, Meyer UA. Cyclosporin metabolism in human liver: Identification of a cytochrome P-450 III gene family as the major cyclosporin-metabolising enzyme explains interactions of cyclosporin with other drugs. Clin Pharmacol Ther 1988; 43: 630-634.
22. du Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993; 24: 435-440.
23. Lindholm A. Therapeutic monitoring of cyclosporine - an update. Eur J Clin Pharmacol 1991; 41: 273-283.
24. Lindholm A. Cyclosporine A: Clinical experience and therapeutic drug monitoring. Ther Drug Monit 1995; 17: 631-637.
25. Best NG, Trull AK, Tan KKC et al. Pharmacodynamics of cyclosporine in heart and heart-lung transplant recipients, I: Blood cyclosporine concentrations and other risk factors for cardiac allograft rejection. Transplantation 1996; 62: 1429-1435.
26. Lindholm A, Henricsson S. Intra- and Interindividual variability in the free fraction of cyclosporin in plasma in recipients of renal transplant. Ther Drug Monit 1989; 11: 623-630.
27. Lindholm A, Henricsson S, Gang P. The free fraction of cyclosporin in plasma: Clinical findings with a new method, Transplant Proc 1988; 20(suppl 2): 377-381.
28. Lindholm A. Monitoring of the free concentration of cyclosporin in plasma in man. Eur J Clin Pharmacol 1991; 40: 571-575.
29. Hladky SB. Pharmacokinetics. Manchester University Press, 1990.
30. Gomez DY, Wacher VJ, Tomlanovich SJ, Herbert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-19.